Moneycontrol Bureau
Shares of Lupin gained nearly a percent intraday Thursday after the pharma major launched birth control pill in the United States yesterday.
"US subsidiary Lupin Pharmaceutical Inc has launched Tri-Lo-Marzia tablets (Norgestimate and Ethinyl Estradiol Tablets USP, 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg) after getting approval from the United States Food and Drug Administration (FDA) to market in the US," says the Mumbai-based pharma company.
Tri-Lo-Marzia is the AB rated generic equivalent of Janssen Pharmaceuticals Inc Ortho Tri-Cyclen Lo tablets. It is indicated for use by women to prevent pregnancy.
The company says Ortho Tri-Cyclen Lo tablets had US sales of USD 488.4 million, according to IMS MAT September 2015.
This product represents Lupin’s 16th oral contraceptive launch in the US. The company has filed 37 oral contraceptive products with the FDA till date.
At 10:13 hours IST, the scrip of Lupin was quoting at Rs 1,761, up Rs 6.85, or 0.39 percent on the BSE.Posted by Sunil Shankar Matkar
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
